Pricing Log in Create free account
Saturday 7 November 2026 Export JYNT’s income statement to Excel — free account

The Joint Corp.

JYNT Healthcare Medical Care Facilities

The Joint Corp.’s revenue for fiscal 2025 (year ended December 2025) was $54.9 million, up 5.24% from fiscal 2024.

Revenue
+14.4%
EPS
+400.0%
Free cash flow
+432.3%

Quarter to June 2026, against a year earlier

6.89 0.48 −6.51%
Market cap
$104.2M
P/E
25.5×
Fwd P/E
20.1×
Dividend yield
—
F-score
7/9
Altman Z
2.39
Beneish M
−2.27
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 1.73
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 2 2 2 — 1 1 — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 16.81%

Capital & Financial Ratios $m

Size
Market Cap 104.24
Revenue ttm 58.55
Net income ttm 3.80
Free cash flow ttm 4.23
Net debt Q (23.00)
Valuation
P/E 25.52
Forward P/E 20.10
Price / sales 1.68
Forward P/S Powerpack
Price / FCF 0.00
Price / book 6.18 (above 6: high)
Financial health
Current ratio Q 1.83 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q +14.41% (above 0%: growing)
Operating income growth Q +67.61% (above 0%: growing)
EPS, this year +1,300.00% (at or above 15%: strong)
EPS, next year A +63.89% (at or above 15%: strong)
Revenue, next year A +10.94% (at or above 10%: strong)
EPS, past 5 yrs −26.73% (below 0%: weak)
EPS, next 5 yrs A +25.00% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 2.5×; over the ten years it ranged from 0.9× in 2023 to 20.6× in 2021.
P/E against its own 10 years 0.07%
10-year low 10-year high
P/S against its own 10 years 7.73%
10-year low 10-year high
P/B against its own 10 years 19.72%
10-year low 10-year high
EV/Sales against its own 10 years 6.74%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 19 26 24 23
Receivables 3 3 3 2
Inventory — — — —
Other — — — —
44 75 52 44
2023 2024 2025 Q'26
Payables 1 2 2 1
ST’ Debt — — — —
Other 3 5 6 4
34 49 33 24

Compound Annual Growth %

10y 5y 3y
Sales 14.78% (1.33%) (18.46%)
Cash Flow 0.00% (30.31%) (39.27%)
Earnings 0.00% (26.07%) 66.78%
Book Value (3.11%) (6.52%) (22.65%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.11 Actual −0.01

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.01 0.02 Beat by 0.03
Q4 FY25 0.05 0.06 Beat by 0.01
Q1 FY26 0.03 0.08 Beat by 0.05
Q2 FY26 0.11 −0.01 Miss by 0.12
Q3 FY26 0.11 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.09 0.05 — — —
’25 0.05 0.01 0.06 0.07 0.19
’24 0.06 (0.24) (0.21) 0.00 (0.38)
’23 0.15 (0.02) (0.05) (0.75) (0.65)
’22 0.00 (0.06) 0.05 0.04 0.04
’21 0.16 0.18 0.13 0.04 0.48
’20 0.06 0.01 0.11 0.72 0.90
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 15 15 — — —
’25 13 13 13 15 55
’24 12 13 13 15 52
’23 28 29 29 31 47
’22 22 25 26 28 101
’21 18 20 21 21 80
’20 14 13 15 17 59
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 2 — — —
’25 (4) 1 2 3 2
’24 3 (1) 3 4 9
’23 6 1 4 3 15
’22 0 (1) 4 5 8
’21 2 7 3 1 14
’20 1 2 4 4 11
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 2 — — —
’25 (4) 0 1 3 0
’24 2 (1) 3 4 8
’23 5 0 3 2 10
’22 (1) (6) 0 3 2
’21 0 4 1 0 7
’20 0 1 4 2 7
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 21 25 37 48 59 80 101 47 52 55 59 +11.6% 61 63 67 +7.0%
Gross margin, % 85.68 87.06 88.24 88.51 88.91 90.42 90.94 77.69 77.92 79.55 81.76 (6.1) pt
EBT (15) (3) 0 3 5 6 1 0 (2) 0 2 (37.2%)
EBT margin, % (73.13) (13.63) 0.30 6.96 9.22 7.57 0.69 0.54 (3.08) (0.42) 3.61 +72.7 pt
Net income (15) (3) 0 3 13 8 1 (10) (6) 3 4 n/m
Per share, $
Per share, $ Revenue 1.62 1.88 2.68 3.51 4.19 5.59 6.99 3.20 3.50 3.63 4.11 +9.4%
Earnings (1.20) (0.25) 0.01 0.24 0.94 0.50 0.04 (0.66) (0.39) 0.19 0.27 n/m
Cash flow (0.85) (0.01) 0.40 0.54 0.80 0.97 0.57 1.00 0.63 0.12 0.38 n/m
Capex (0.15) (0.03) (0.08) (0.30) (0.30) (0.49) (0.41) (0.34) (0.08) (0.10) (0.08) (4.4%)
Free cash flow (1.00) (0.04) 0.32 0.24 0.50 0.48 0.16 0.66 0.55 0.02 0.30 n/m
Book value 0.55 0.09 0.05 0.41 1.51 2.12 2.25 1.69 1.39 1.00 1.11 +6.9%
Shares, m 13 13 14 14 14 14 14 15 15 15 15 +2.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 770.37 70.17 28.24 125.70 451.48 0.00 0.00 45.89 25.52 149.2
P/S 1.64 2.60 3.10 4.60 6.27 11.76 1.97 1.18 3.04 2.40 1.68 3.9
P/B 4.86 56.27 156.30 38.99 17.41 31.04 6.12 5.60 7.67 8.75 6.18 33.3
EV/Sales 1.48 2.47 2.89 4.47 5.99 11.56 1.91 1.05 2.58 2.00 1.32 3.6
EV/FCF (2.39) (72.59) 26.38 90.43 62.54 169.20 (65.11) 28.07 45.56 (22.20) (73.73) 26.0
Cash, $m
Cash, $m Operating cash flow (11) 0 5 8 11 14 8 15 9 2 5 n/m
Capex (2) 0 (1) (4) (4) (7) (6) (5) (1) (2) (1) (2.5%)
Free cash flow (13) (1) 4 3 7 7 2 10 8 0 4 n/m
Balance, $m
Balance, $m Working capital 0 1 1 0 7 5 (6) 11 26 19 20 n/m
Net debt (3) (3) (8) (6) (16) (18) (8) (17) (26) (24) (23) +26.1%
Shareholders’ equity 7 1 1 6 21 30 33 25 21 15 16 +9.0%
Returns, %
Returns, % ROA (60.19) (19.34) 0.70 9.90 24.03 9.89 0.69 (10.79) (6.81) 4.03 6.09 +64.2 pt
ROIC (239.74) 0.00 0.00 0.00 66.43 30.67 2.15 2.63 0.00 0.00 0.00 +239.7 pt
ROE (109.94) (84.97) 15.60 103.09 98.09 29.42 1.99 (34.00) (25.51) 16.26 19.41 +126.2 pt
People
People Employees 94 148 138 150 425 601 781 794 736 330 — +15.0%
Revenue/emp, $m 0.22 0.17 0.27 0.32 0.14 0.13 0.13 0.06 0.07 0.17 — (3.0%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

The Joint Corp. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AUNA Auna S.A. $339.7M 66.7× 6.1× +20.51% (above 0%: growing) −61.29% (below 0%: shrinking) +121.08% (above 0%: growing) 35.72% 13.09% Compare
CYH Community Health Systems, Inc. $321.5M 4.2× — (loss-making) −10.69% (below 0%: shrinking) n/m +857.14% (above 0%: growing) 85.24% 5.30% Compare
JYNT The Joint Corp. $104.2M 25.5× 20.1× +14.41% (above 0%: growing) +400.00% (above 0%: growing) +432.31% (above 0%: growing) 83.68% (2.43%)
AIRS AirSculpt Technologies, Inc. $103.8M — (loss-making) — (loss-making) −8.71% (below 0%: shrinking) n/m −813.83% (below 0%: shrinking) 0.00% 0.00% Compare
PARK Park Dental Partners, Inc. $95.8M — (loss-making) — +12.15% (above 0%: growing) −65.84% (below 0%: shrinking) −34.78% (below 0%: shrinking) 14.37% 1.90% Compare
BMGL Basel Medical Group Ltd $70.5M — — — — — — — Compare
CCEL Cryo-Cell International Inc. $39.9M — (loss-making) 65.1× −0.02% (below 0%: shrinking) +77.78% (above 0%: growing) −58.37% (below 0%: shrinking) 79.38% 28.04% Compare
BTMD biote Corp. $37.4M 6.6× — (loss-making) −9.48% (below 0%: shrinking) n/m −174.16% (below 0%: shrinking) 65.38% (7.93%) Compare
PIII P3 Health Partners Inc. $28.1M — (loss-making) — +8.60% (above 0%: growing) n/m −272.24% (below 0%: shrinking) 22.26% 10.67% Compare
Median of peers $83.1M 6.6× — −0.02% −61.29% −58.37% 35.72% 5.30%

All 51 Medical Care Facilities stocks →

Pay and ownership Proxy statement filed 7 April 2026

Ownership

Directors and executive officers, together 30.20%
Jefferson Gramm 27.50%
Bandera Partners LLC 27.50%
Charles E. Jobson 11.50%
The Vanguard Group Inc. 6.30%
BlackRock Fund, Inc. 6.20%
Skylands Capital, LLC. 6.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

The Joint Corp. (JYNT) Latest News

6 Nov

Impact 3 · · MarketBeat
Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com

5 Nov

Impact 3 · · GlobeNewswire

22 Oct

Impact 3 · · GlobeNewswire

6 Oct

Impact 4 · · PR Newswire

13 Aug

Impact 4 · · The Motley Fool transcript

7 Aug

Impact 4 · · Moby transcript
Impact 4 · transcript
Impact 3 · · MarketBeat

6 Aug

Impact 3 ·
Impact 3 ·

8 May

Impact 4 · · MarketBeat

7 May

Impact 4 · · Zacks
Impact 4 · · Moby
Impact 3 ·

27 Apr

Impact 4 · · GlobeNewswire

29 Mar

Impact 4 · · Simply Wall St.

13 Mar

Impact 4 · · Moby

12 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool transcript
Impact 4 · · Zacks
Impact 4 · · GlobeNewswire

16 Jan

Impact 3 · · Simply Wall St.

5 Jan

Impact 3 · · GlobeNewswire

24 Dec

Impact 3 · · Simply Wall St.

11 Dec

Impact 3 · · GlobeNewswire

3 Dec

Impact 4 · · Simply Wall St.

17 Nov

Impact 3 · · Zacks
stockrow.com/JYNT · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com